In summary, we show that NCOA4–RET and LMNA–NTRK1 fusions, along with NRG1 and GNAS amplifications, are potentially novel cetuximab-resistance (intrinsic) alterations in patients with KRAS wt CRC. Here, NTRK1 is linked to colorectal carcinoma.